Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc
Therapy for infection with HIV-2 remains limited. We report an HIV-2-infected patient in whom genotyping demonstrated PI, NRTI and NNRTI resistance, with a subsequent response to raltegravir- and maraviroc-based therapy. Further studies are required to assess the clinical efficacy of maraviroc in HI...
Gespeichert in:
| Veröffentlicht in: | Antiviral research 2010-05, Vol.86 (2), p.224-226 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 226 |
|---|---|
| container_issue | 2 |
| container_start_page | 224 |
| container_title | Antiviral research |
| container_volume | 86 |
| creator | Armstrong-James, Darius Stebbing, Justin Scourfield, Andrew Smit, Erasmus Ferns, Bridget Pillay, Deenan Nelson, Mark |
| description | Therapy for infection with HIV-2 remains limited. We report an HIV-2-infected patient in whom genotyping demonstrated PI, NRTI and NNRTI resistance, with a subsequent response to raltegravir- and maraviroc-based therapy. Further studies are required to assess the clinical efficacy of maraviroc in HIV-2 infection. |
| doi_str_mv | 10.1016/j.antiviral.2010.02.324 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_877570388</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0166354210003840</els_id><sourcerecordid>877570388</sourcerecordid><originalsourceid>FETCH-LOGICAL-c432t-21c080bc18e4f58bab7643ba0aab2a05ed948667c83b1c3316d2f2a1613a731a3</originalsourceid><addsrcrecordid>eNqFkcFO3DAQhi1EBVvgFYovqKdsx3ZiO0e0ogUJqRfK1Zo4E-pVNgHbC-Lta7pbeuRka_SN_5nPjJ0LWAoQ-tt6iVMOzyHiuJRQqiCXStYHbCGskVULrT5ki0LqSjW1PGafU1oDgDatPWLHEqQQulELdrcawxQ8jnzeZj9viIeJR0oh5ZLAr2_uK1lKA_kc5onnSJip5y8h_-YlPNNDxDIGx6nnG_x7n_0p-zTgmOhsf56wX9-v7lbX1e3PHzery9vK10rmSgoPFjovLNVDYzvsjK5Vh4DYSYSG-ra2WhtvVSe8UkL3cpAotFBolEB1wr7u3n2M89OWUnabkDyNI040b5OzxjQGlLUfkkYpBSDbppBmR_o4pxRpcI8xlM1enQD35t6t3bt79-begXTFfen8ss_Ydhvq3_v-yS7AxR7AVIwPEScf0n9OatsoLQt3ueOouHsOFF3ygSZPfYjlH1w_hw-H-QO48KZC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733300295</pqid></control><display><type>article</type><title>Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Armstrong-James, Darius ; Stebbing, Justin ; Scourfield, Andrew ; Smit, Erasmus ; Ferns, Bridget ; Pillay, Deenan ; Nelson, Mark</creator><creatorcontrib>Armstrong-James, Darius ; Stebbing, Justin ; Scourfield, Andrew ; Smit, Erasmus ; Ferns, Bridget ; Pillay, Deenan ; Nelson, Mark</creatorcontrib><description>Therapy for infection with HIV-2 remains limited. We report an HIV-2-infected patient in whom genotyping demonstrated PI, NRTI and NNRTI resistance, with a subsequent response to raltegravir- and maraviroc-based therapy. Further studies are required to assess the clinical efficacy of maraviroc in HIV-2 infection.</description><identifier>ISSN: 0166-3542</identifier><identifier>EISSN: 1872-9096</identifier><identifier>DOI: 10.1016/j.antiviral.2010.02.324</identifier><identifier>PMID: 20211653</identifier><identifier>CODEN: ARSRDR</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Anti-HIV Agents - therapeutic use ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Cyclohexanes - therapeutic use ; Drug Resistance, Viral ; Genotype ; Genotyping ; HIV Infections - drug therapy ; HIV Infections - virology ; HIV-2 ; HIV-2 - isolation & purification ; Human immunodeficiency virus 2 ; Human viral diseases ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infectious diseases ; Maraviroc ; Medical sciences ; Outcome ; Pharmacology. Drug treatments ; Pyrrolidinones - therapeutic use ; Raltegravir ; Raltegravir Potassium ; RNA, Viral - genetics ; Treatment Outcome ; Triazoles - therapeutic use ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids</subject><ispartof>Antiviral research, 2010-05, Vol.86 (2), p.224-226</ispartof><rights>2010 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c432t-21c080bc18e4f58bab7643ba0aab2a05ed948667c83b1c3316d2f2a1613a731a3</citedby><cites>FETCH-LOGICAL-c432t-21c080bc18e4f58bab7643ba0aab2a05ed948667c83b1c3316d2f2a1613a731a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.antiviral.2010.02.324$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22685362$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20211653$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Armstrong-James, Darius</creatorcontrib><creatorcontrib>Stebbing, Justin</creatorcontrib><creatorcontrib>Scourfield, Andrew</creatorcontrib><creatorcontrib>Smit, Erasmus</creatorcontrib><creatorcontrib>Ferns, Bridget</creatorcontrib><creatorcontrib>Pillay, Deenan</creatorcontrib><creatorcontrib>Nelson, Mark</creatorcontrib><title>Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc</title><title>Antiviral research</title><addtitle>Antiviral Res</addtitle><description>Therapy for infection with HIV-2 remains limited. We report an HIV-2-infected patient in whom genotyping demonstrated PI, NRTI and NNRTI resistance, with a subsequent response to raltegravir- and maraviroc-based therapy. Further studies are required to assess the clinical efficacy of maraviroc in HIV-2 infection.</description><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Cyclohexanes - therapeutic use</subject><subject>Drug Resistance, Viral</subject><subject>Genotype</subject><subject>Genotyping</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - virology</subject><subject>HIV-2</subject><subject>HIV-2 - isolation & purification</subject><subject>Human immunodeficiency virus 2</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Infectious diseases</subject><subject>Maraviroc</subject><subject>Medical sciences</subject><subject>Outcome</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrrolidinones - therapeutic use</subject><subject>Raltegravir</subject><subject>Raltegravir Potassium</subject><subject>RNA, Viral - genetics</subject><subject>Treatment Outcome</subject><subject>Triazoles - therapeutic use</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><issn>0166-3542</issn><issn>1872-9096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFO3DAQhi1EBVvgFYovqKdsx3ZiO0e0ogUJqRfK1Zo4E-pVNgHbC-Lta7pbeuRka_SN_5nPjJ0LWAoQ-tt6iVMOzyHiuJRQqiCXStYHbCGskVULrT5ki0LqSjW1PGafU1oDgDatPWLHEqQQulELdrcawxQ8jnzeZj9viIeJR0oh5ZLAr2_uK1lKA_kc5onnSJip5y8h_-YlPNNDxDIGx6nnG_x7n_0p-zTgmOhsf56wX9-v7lbX1e3PHzery9vK10rmSgoPFjovLNVDYzvsjK5Vh4DYSYSG-ra2WhtvVSe8UkL3cpAotFBolEB1wr7u3n2M89OWUnabkDyNI040b5OzxjQGlLUfkkYpBSDbppBmR_o4pxRpcI8xlM1enQD35t6t3bt79-begXTFfen8ss_Ydhvq3_v-yS7AxR7AVIwPEScf0n9OatsoLQt3ueOouHsOFF3ygSZPfYjlH1w_hw-H-QO48KZC</recordid><startdate>20100501</startdate><enddate>20100501</enddate><creator>Armstrong-James, Darius</creator><creator>Stebbing, Justin</creator><creator>Scourfield, Andrew</creator><creator>Smit, Erasmus</creator><creator>Ferns, Bridget</creator><creator>Pillay, Deenan</creator><creator>Nelson, Mark</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>20100501</creationdate><title>Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc</title><author>Armstrong-James, Darius ; Stebbing, Justin ; Scourfield, Andrew ; Smit, Erasmus ; Ferns, Bridget ; Pillay, Deenan ; Nelson, Mark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c432t-21c080bc18e4f58bab7643ba0aab2a05ed948667c83b1c3316d2f2a1613a731a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Cyclohexanes - therapeutic use</topic><topic>Drug Resistance, Viral</topic><topic>Genotype</topic><topic>Genotyping</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - virology</topic><topic>HIV-2</topic><topic>HIV-2 - isolation & purification</topic><topic>Human immunodeficiency virus 2</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Infectious diseases</topic><topic>Maraviroc</topic><topic>Medical sciences</topic><topic>Outcome</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrrolidinones - therapeutic use</topic><topic>Raltegravir</topic><topic>Raltegravir Potassium</topic><topic>RNA, Viral - genetics</topic><topic>Treatment Outcome</topic><topic>Triazoles - therapeutic use</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Armstrong-James, Darius</creatorcontrib><creatorcontrib>Stebbing, Justin</creatorcontrib><creatorcontrib>Scourfield, Andrew</creatorcontrib><creatorcontrib>Smit, Erasmus</creatorcontrib><creatorcontrib>Ferns, Bridget</creatorcontrib><creatorcontrib>Pillay, Deenan</creatorcontrib><creatorcontrib>Nelson, Mark</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Antiviral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Armstrong-James, Darius</au><au>Stebbing, Justin</au><au>Scourfield, Andrew</au><au>Smit, Erasmus</au><au>Ferns, Bridget</au><au>Pillay, Deenan</au><au>Nelson, Mark</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc</atitle><jtitle>Antiviral research</jtitle><addtitle>Antiviral Res</addtitle><date>2010-05-01</date><risdate>2010</risdate><volume>86</volume><issue>2</issue><spage>224</spage><epage>226</epage><pages>224-226</pages><issn>0166-3542</issn><eissn>1872-9096</eissn><coden>ARSRDR</coden><abstract>Therapy for infection with HIV-2 remains limited. We report an HIV-2-infected patient in whom genotyping demonstrated PI, NRTI and NNRTI resistance, with a subsequent response to raltegravir- and maraviroc-based therapy. Further studies are required to assess the clinical efficacy of maraviroc in HIV-2 infection.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>20211653</pmid><doi>10.1016/j.antiviral.2010.02.324</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0166-3542 |
| ispartof | Antiviral research, 2010-05, Vol.86 (2), p.224-226 |
| issn | 0166-3542 1872-9096 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_877570388 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Anti-HIV Agents - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Cyclohexanes - therapeutic use Drug Resistance, Viral Genotype Genotyping HIV Infections - drug therapy HIV Infections - virology HIV-2 HIV-2 - isolation & purification Human immunodeficiency virus 2 Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Maraviroc Medical sciences Outcome Pharmacology. Drug treatments Pyrrolidinones - therapeutic use Raltegravir Raltegravir Potassium RNA, Viral - genetics Treatment Outcome Triazoles - therapeutic use Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids |
| title | Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T23%3A05%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20outcome%20in%20resistant%20HIV-2%20infection%20treated%20with%20raltegravir%20and%20maraviroc&rft.jtitle=Antiviral%20research&rft.au=Armstrong-James,%20Darius&rft.date=2010-05-01&rft.volume=86&rft.issue=2&rft.spage=224&rft.epage=226&rft.pages=224-226&rft.issn=0166-3542&rft.eissn=1872-9096&rft.coden=ARSRDR&rft_id=info:doi/10.1016/j.antiviral.2010.02.324&rft_dat=%3Cproquest_cross%3E877570388%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733300295&rft_id=info:pmid/20211653&rft_els_id=S0166354210003840&rfr_iscdi=true |